The largest database of trusted experimental protocols

Terbinafine

Manufactured by Novartis
Sourced in China

Terbinafine is a laboratory equipment product designed for use in research and analysis. It is a synthetic antifungal agent that inhibits the biosynthesis of ergosterol, an essential component of fungal cell membranes. The core function of Terbinafine is to provide a tool for researchers and scientists to study and investigate fungal organisms and their susceptibility to antifungal compounds.

Automatically generated - may contain errors

4 protocols using terbinafine

1

Evaluating Terbinafine Sensitivity in Arabidopsis Seedlings

Check if the same lab product or an alternative is used in the 5 most similar protocols
Seeds were sterilized and sown on solid MS supplemented with terbinafine (kindly supplied by Novartis; www.novartis.com) to final concentrations of 0, 0.1, 0.25, 0.5, and 1 mM, prepared from a 100 mM terbinafine stock solution in DMSO. The final concentration of DMSO was kept constant in all plates regardless of the final concentration of the inhibitor. Plates were grown at 22 C under a short-day photoperiod. Quantification of plant sensitivity to terbinafine was measured by the percentage of seedlings that developed true green leaves after 23 days.
+ Open protocol
+ Expand
2

Antifungal Susceptibility Testing of Clinical Isolates

Check if the same lab product or an alternative is used in the 5 most similar protocols
The clinical isolate was subjected to antifungal susceptibility testing according to CLSI guidelines (M38-A document), as previously described [3 (link), 18 (link)], and the MICs of antifungal combinations were determined according to previously described methods [3 (link), 18 (link)]. Itraconazole (Xian-Janssen Pharmaceutical Ltd. Xi’ an, China), terbinafine (Beijing Novartis Pharmaceutical Ltd. (Beijing, China)) and voriconazole (Sigma, USA) were dissolved in 100% DMSO as a stock solution (3200 μg/mL). Drugs were diluted to obtain final concentrations, with Itraconazole and voriconazole from 0.008 to 8 μg/mL and terbinafine from 0.008 to 0.5 μg/mL. Isolates were sub-cultured, and spores from colonies were collected and adjusted with saline to achieve an inoculum concentration of 106 conidia/mL. Each suspension was diluted 1:50–100 with RPMI 1640 to obtain the final test inoculum (0.4–5×104 conidia/mL). Conidial suspension of each of the tested strains were cultivated on RPMI 1640 medium for 7 days at 35°C. Candida parapsilosis ATCC22019 (CBS604), obtained from Centraalbureau voor Schimmelcultures (CBS, the Netherlands), was used as a quality control. The final test inoculum concentration was 0.5–2.5×103 conidia/mL.
+ Open protocol
+ Expand
3

Antifungal Sensitivity Testing of Dermatophytes

Check if the same lab product or an alternative is used in the 5 most similar protocols
The broth micro-dilution method (according to CLSI M38-A2 guidelines [33 ]) was used for testing the sensitivity of the dermatophyte isolates to the most commonly used antifungal drugs. Fluconazole was obtained from Pfizer International (New York, NY, USA), itraconazole, and miconazole were obtained from the Janssen Research Foundation (Beerse, Belgium), griseofulvin was purchased from Sigma Chemical Company (St. Louis, MO, USA), and terbinafine was purchased from Novartis (Basel, Switzerland). All drugs were dissolved in dimethyl sulfoxide (DMSO, Sigma-Aldrich), with the exception of Fluconazole, which was dissolved in RPMI1640 medium (Sigma Co. St. Louis, USA), buffered at pH 7.0 with 165 mM of 3-(N-morpholino) propanesulfonic acid (MOPS; Sigma), and serially diluted two-fold to final concentrations of 0.125–64 μg/mL for Fluconazole and 0.03–16 μg/mL for the other antifungal agents. MIC values, MIC50, and MIC90 were determined.
+ Open protocol
+ Expand
4

Antifungal Susceptibility Testing Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
The clinical isolate was submitted to antifungal susceptibility testing according to CLSI guidelines (M38-A document) as previously described [3 (link), 10 (link)], and the MICS of antifungal combination was according to previously described [3 (link), 10 (link)]. Itraconazole (Xian-Janssen Pharmaceutical Ltd. Xi’an, China), terbinafine (Beijing Novartis Pharmaceutical Ltd., Beijing, China) and voriconazole (Sigma, USA) were dissolved in 100 % DMSO as stock solution (3,200 µg/mL). Drugs were diluted to obtain the final concentrations, with Itraconazole and voriconazole from 0.008 to 8 µg/mL and terbinafine from 0.008 to 0.5 µg/mL. The isolates were subcultured, and the spores of the colonies were collected and adjusted with saline to achieve an inoculum concentration of 106 conidia/mL. Each suspension was diluted 1:50–100 with RPMI 1640 to obtain the final test inoculum (0.4–5 9 104 conidia/mL). Suspension of conidia of each the tested strains was cultivated on RPMI 1640 medium for 7 days at 35 °C. Candida parapsilosis ATCC22019 (CBS604), obtained from Centraalbureau voor Schimmelcultures (CBS, the Netherlands), was used as a quality control. The final test inoculum concentration was 0.5–2.5 × 103 - conidia/mL.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!